A new clinical trial will further assess the role of bevacizumab (Avastin) in patients with previously untreated metastatic bowel cancer.
Avastin is known to be effective in stopping or slowing down the growth of cancers by disrupting the blood supply to the affected site.
It is currently available for use in patients with advanced bowel cancer and others including brain, lung, and kidney cancers.
The new study will combine Avastin with other chemotherapy drugs – initially combinations known as XELOX or mFOLFOX6. If the disease continues to progress, patients can be switched to a different combination of Avastin and FOLFIRI.
About 150 patients will be recruited into the Phase IV study to help document the longer term safety and effectiveness of Avastin at different stages of the disease.
The study will also help establish if and how a simple blood test can help predict the progression of disease.
The benefits of participating in such clinical trials include close monitoring during the trial, access to otherwise expensive new treatments, and the satisfaction of contributing to better understanding of cancer and its management.
The ASCENT study will be underway for about two years in leading hospitals in metropolitan and regional Australia. Patients who are interested in participating in the study are advised to talk to their oncologist about their eligibility.
For a list of sites where the trial is being conducted in Australia visit Avastin (Bevacizumab) - ASCENT study on ClinicalTrials.gov website.